Aurobindo Pharma receives tentative approval for its Abacavir Sulfate tablets

Aurobindo Pharma Limited is pleased to announce that it has received the tentative approval to manufacture and market Abacavir Sulfate tablets 60mg from the US Food & Drug Administration (USFDA).

The New Drug Application (NDA) 22-293 provides for the use of Abacavir Sulfate 60mg Tablets in combination with other antiretrovirals for use in pediatric patients for the treatment of HIV-1 infection.

The company had earlier received tentative approvals to Abacavir Sulfate Tablets 300mg and Abacavir Sulfate Oral Solution 20mg/mL

This is Aurobindo's 77th ANDA approval from USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpeth, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com